This technology allows phenotypic screening to discover new compounds and new targets for complex diseases, such as neurodegenerative diseases and cancer
HCS main assets for active cosmetic ingredients
Confirming the efficacy of nutraceuticals and functional food is a key for the development of new compounds. High content in vitro assays play a role in researching and developing new actives ingredients dedicated to human and animals food.
Phenotypic screening by High Content Screening allows analysing toxic events, as genotoxicity, hepatotoxicity, neurotoxicity or cardiotoxicity at the early stage of research.
BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
Are you curious about confocal microscopy and the advantages of spinning disk? This article from Teledyne Imaging explains the technology with really simple words. You will understand why we have chosen this way to create Read more…
It will a short article today to wish you a wonderful Christmas and all our best wish for this new year! We don’t known how will be 2020 but we are optimistic : We will Read more…
Biomimesys is providing a great opportunity to culture human induced pluripotent stem cells (hiPSCs) in 3D and differentiate them into different kind of cell types including liver cells. Showcased by Méryl Roudaut at the 20th Read more…
Ask for high quality link by putting your email below We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs Read more…
Stroke is the second leading cause of death worldwide and the most common cause of disability in adults. Ischemic stroke represents 80% of the cases. They cause oxygen and glucose deficit in the brain, leading Read more…
Nathalie and Elodie were in Marseille last week for BioFit event, where we had a booth under Clubster NHL (Nutrition-Health-Longevity) Pavilion: We would like to thank all the participants and collaborators who came to see Read more…
Last week, it was a great pleasure to meet our partners during the kick-off meeting of ScaLABle-MEAT project, funded by EUREKA and the national funding agencies associated with the Eurostars program. It was held in Read more…
Nathalie and Elodie will be present in Marseille for BioFit event next week! Indeed, HCS Pharma has a booth in Clubster NSL’s pavilion (number I20). Just stop by 🙂 It will be a pleasure to Read more…
If you work in 3D cell culture, you should know our innovative technology BIOMIMESYS® just recognized as a Deep Tech Pionner by Hello Tomorrow. We have more and more practical examples of uses by our Read more…
Among more than 5,000 applicants from 128 different countries, HCS Pharma has been selected by Hello Tomorrow as one of “Deep Tech Pioneers” from their annual Global Challenge 2020 with our groundbreaking technology BIOMIMESYS®! BIOMIMESYS® Read more…
In 2019, Océane obtained her Master’s degree student in biotechnology specializing in production, purification and characterization of biomolecules at the ENSTBB (Bordeaux). After a three-month internship at IDEA Lab in vitro and a five-month internship Read more…
We were in Taiwan few weeks ago, invited by our partner Molecular Devices to talk about our skills in 3D cell culture, with our unique groundbreaking technology BIOMIMESYS® and our services for in vitro screening Read more…
The 2nd congress of Centers of Excellence in Neurodegeneration (CoEN) took place in Lille on the 14th and 15th of November 2019. It was organized by the Lille Center of Excellence for Neurodegenerative Disorders (LICEND). Read more…
James W. Fawcett published the review « The extracellular matrix in plasticity and regeneration after CNS injury and neurodegenerative disease » in 2015, highlighting the key role of the chondroitin sulfate proteoglycans (CSPGs) of the Read more…
Last week, our study director Elodie was in Rennes to participate in NutrEvent! We had a booth there, under NSL Clubster pavilion (Lille Northern France Health and Nutrition clubster). It was a pleasure for her Read more…
The status of Young Innovative Company (JEI) recognize young companies very active in R&D. this distinction is given by the french ministry of research.
Led by Pr Bertrand Cariou, director of l’institut du thorax*, the project aims at improving the management of hypercholesterolemia by identifying new markers in cardiovascular risk and new targets of LDL-cholesterol metabolism, which plays a central role in the development and progression of cardiovascular diseases.
This project aims at developing a universal “plug and play” platform, flexible and modular, mimicking the major events occurring in the liver sinusoid: barrier/sieving effect resulting from the specific fenestration of liver sinusoidal endothelial cells, biotransformation and metabolism in the hepatocytes themselves.
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.